[1] POUTON C W.Formulation of poorly water-soluble drugs for oral administration： physicochemical and physiological issues and the lipid formulation classification system[J] . Eur J Pharm Sci，2006，29(3-4)： 278-287. [2] POTER C J H，CHARMAN W N. Uptake of drugs into the intestinal lymphatics after oral administration[J] . Adv Drug Deliv Rev，1997，25(1)： 71-89. [3] POTER C J H，CHARMAN W N. Intestinal lymphatic drug transport： an update[J] . Adv Drug Deliv Rev，2001，50(1-2)： 61-80. [4] O′DRISCOLL C M. Lipid-based formulations for intestinal lymphatic delivery[J] . Eur J Pharm Sci，2002，15(5)： 405-415. [5] EDWARDS G A，POTER C J H，CALIPH S M，et al. Animal models for the study of intestinal lymphatic drug transport[J] . Adv Drug Deliv Rev，2001，50(1-2)： 45-60. [6] MU H L，HY C E. The digestion of dietary triacylglycerols[J] . Prog Lipid Res，2004，43(2)：105-133. [7] CHARMAN W N，PORTER C J H，MITHANI S，et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption： the role of lipids and pH[J] . J Pharm Sci，1997，86(3)：269-282. [8] SEEBALLUCK F，ASHFORD M B，O′DRISCOLL C M. Copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells[J] . Pharm Res，2003，20(7)： 1085-1092. [9] SEEBALLUCK F，LAWLESS E，ASHFORD M B，et al. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate： in vitro and in vivo correlation using Caco-2 cells and cannulated rat intestinal lymphatic model[J] . Pharm Res，2004，21(12)： 2320-2326. [10] KARPF D M，HOLM R，GARAFALO C，et al. Effect of different surfactants in biorelevant medium on the secretion of a lipophilic compound in lipoproteins using Caco-2 cell culture[J] . J Pharm Sci，2006，95(1)： 45-55. [11] LANGHEIM S，YU L，VON BERQMANN K，et al. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile[J] . J Lipid Res，2005，46(8)： 1732-1738. [12] POTER C J H，CHARMAN S A，CHARMAN W N. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model： effect of lipid vehicle dispersion[J] . J Pharm Sci，1996，85(4)：351-356. [13] BOYD M，RISOVIC V，JULL P，et al. A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations： cannulation of the mesenteric and thoracic lymph ducts within the rat[J] . J Pharmacol Toxicol Methods，2004，49(2)：115-120. [14] POTER C J H，CHARMAN S A，HUMBERSTONE A J，et al. Lymphatic transport of Halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt： effect of lipid class and lipid vehicle dispersion[J] . J Pharm Sci，1996，85(4)：357-361. [15] HAUSS D，FOGAL S，FICORILLI J. Chronic collection of mesenteric lymph from conscious，tethered rats[J] . Contemp Tropics Lab Anim Sci，1998，37(3)： 56-58. [16] DAHAN A，HOFFMAN A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs[J] . Eur J Pharm Sci，2005，24(4)：381-388. [17] WHITE D G，STORY M J，BARNWELL S G. An experimental animal model for studying the effects of a novel lymphatic drug delivery system for propranolol[J] . Int J Pharm，1991，69(2)：139-174. [18] KHOO S M，EDWARDS G A，POTER C J H，et al. A conscious dog model for assessing the absorption，enterocyte-based metabolism，and intestinal lymphatic transport of halofantrine[J] . J Pharm Sci，2001，90(10)： 1599-1607. [19] LESPINE A，CHANOIT G，MELOU B A，et al. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs[J] . Eur J Pharm Sci，2006，27(1)： 37-43. [20] YOSHIKAWA H，TAKADA K，MURANISHI S. Molecular wei- ght dependence of permselectivity to rat small intestinal blood-lymph barrier for exogenous macromolecules absorbed from lumen[J] . J Pharmacobiodyn，1984，7(1)： 1-6. [21] HOLM R，HOEST J. Successful in silico predicting of intestinal lymphatic transfer [J] . Int J Pharm，2004，272(1-2)： 189-193. [22] CHARMAN W N，STELLA V J. Estimating the maximal potential for intestinal lymphatic of lipophilic drug molecules[J] . Int J Pharm，1986，34(1-2)： 175-178. [23] DE SMIDT P C，CAMPANERO M A，TROCNIZ I F. Intestinal absorption of penclomedine from lipid vehicles in the conscious rat： contribution of emulsification versus digestibility[J] . Int J Pharm，2004，270(1-2)： 109-118. [24] GERSHKOVICH P，HOFFMAN A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons： linear correlation with intestinal lymphatic bioavailability[J] . Eur J Pharm Sci，2005，26(5)： 394-404. [25] KHOO S M，SHACKLEFORD D M，PORTER C J H，et al. Intestinal lymphatic transport of Halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs[J] . Pharm Res，2003，20(9)： 1460-1465. [26] CALIPH S M，CHARMAN W N，POTER C J H. Effect of short-，medium-，and long-chain fatty acid-based vehicles on absolute oral bioavailability and intestinal lymphatic transport of Halofantrine and assessment mass balance in lymph-cannulated and non-cannulated rats[J] . J Pharm Sci，2000，89(8)： 1073-1084. [27] HOLM R，M LLERTZ A，PEDERSEN G P，et al. Comparison of the lymphatic transport of Halofantrine administered in disperse systems containing three different unsaturated fatty acids[J] . Pharm Res，2001，18(9)： 1299-1304. [28] HOLM R，PORTER C J H，EDWARDS G A，et al. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems(SMEDDS) containing structured triglycerides[J] . Eur J Pharm Sci，2006，20 (1)：91-97. [29] HOLM R，PORSGARD T，POTER C J H，et al. Lymphatic fatty acids in canine dosed with pharmaceutical formulations containing structured triacylglycerols[J] . Eur J Lipid Sci Technol，2006，108(9)： 714-722. [30] HAUSS D J，FOGAL S E，FLCORILL J V，et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor[J] . J Pharm Sci，1998，87(2)： 164-169. [31] IWANAGA K，KUSHIBIKI T，MIYAZAKI M，et al. Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs[J] . Biol Pharm Bull，2006，29(3)： 508-512. [32] LING S S N，MAGOSSO E，KARIM N，et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes[J] . Drug Dev Ind Pharm，2006，32(3)： 335-345. [33] BARGONI A，CAVALLI R，CAPUTO O，et al. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats[J] . Pharm Res，1998，15(5)： 745-750. [34] CAVALLI R，BARGONI A，PODIO V，et al. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin[J] . J Pharm Sci，2003，92(5)： 1085-1094. [35] ZHANG J M，HU F Q，YING X Y，et al. Studies on insulin-loaded stearylamine nanoparticles： preparation and physicochemical properties[J] . Chin Pharm J(中国药学杂志)，2004，39(8)：605-607. [36] GRIFFIN B T，O′DRISCOLL C M. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetized rat model[J] . J Pharm Pharmacol，2006，58(7)： 917-925. [37] HUSSAIN N，JAITLEY V，FLORENCE A T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics[J] . Adv Drug Deliv Rev，2001，50(1-2)： 107-172.